Последние новости
随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
。同城约会对此有专业解读
Cloudflare chief technology officer Dane Knecht wrote in reply to Graham’s post that he agreed with Graham, linking back to a post he made earlier this year in which he claimed taste will be the differentiator in engineering in 2026.，更多细节参见WPS下载最新地址
Walmart to pay $100m over claims it misled drivers over pay，详情可参考heLLoword翻译官方下载
'Extraordinary' scale